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The sixth World Kidney Day, an annual event jointly sponsored by the Inter-national Society of Nephrology and the International Federation of Kidney 
Foundations, will be celebrated on 10 March 
2011. Since its inception in 2006, World Kidney 
Day has grown dramatically to become the most 
widely celebrated event associated with kidney 
disease in the world and the most successful 
effort to raise awareness among both the general 
public and government health officials about the 
dangers of kidney disease, especially chronic 
kidney disease (CKD).
In 2011, World Kidney Day will call attention 
to the large, and often unappreciated, role played 
by kidney dysfunction in increasing premature 
cardiovascular disease (CVD), the most common 
cause of morbidity and mortality worldwide.
Can a focus on early detection and prevention 
of kidney disease really improve long-term car-
diovascular health? In this Editorial, we hope to 
convey the message that increased attention to 
the kidneys will indeed improve long-term health 
outcomes by reducing both kidney and cardio-
vascular disease and should therefore be a central 
component of any global health strategy intended 
to reduce the enormous and growing burden of 
chronic non-communicable disease (NCD).
Cardiovascular disease and the kidney
CVD is the most common of the chronic NCDs 
that impact global mortality. About 30% of all 
deaths worldwide and 10% of all healthy life 
lost to disease are accounted for by CVD alone. 
Although there has been some decline in mortal-
ity from CVD in developed countries, no such 
decline has occurred in developing countries, in 
ethnic and socially disadvantaged minority popu-
lations, or in people with accompanying CKD.
The presence of CKD significantly increases the 
risk of a cardiovascular (CV) event in both diabetes 
and hypertension. However, less well appreciated 
is that CKD alone is a strong risk factor for CVD, 
independent of diabetes, hypertension, or any 
other conventional CVD risk factor. This is espe-
cially true when an increase in proteinuria, a major 
target of any CKD screening program, is present.
The 20- to 30-fold increase in CVD in patients 
with end-stage renal disease has long been recog-
nized, but the increased risk for CVD associated 
with lesser degrees of renal-functional impairment 
was definitively demonstrated only in 2004, when 
an independent and graded association between 
glomerular filtration rate (GFR) and risk of death, 
CV events, and hospitalizations was reported in a 
community-based study of over 1000 individuals.
Is this dramatic increase in CVD risk associated 
with CKD really due to CKD, or does it just reflect 
the coexistent diabetes or hypertension that is 
present in a majority of these patients? The inde-
pendent effect of CKD alone has now been well 
documented in many studies. The risk of cardiac 
death is increased by 46% in people with a GFR 
between 30 and 60 ml/min (stage III CKD) inde-
pendent of traditional CV risk factors, including 
diabetes and hypertension. The increased risk of 
CV events and mortality in people over 55 with 
CKD alone is equivalent to, or even higher than, 
that seen in patients with diabetes or previous 
myocardial infarcts. Both general and high-risk 
populations exhibit an increased risk of CVD with 
CKD. This increased risk of CVD is not confined 
to the elderly; in volunteers with an average age of 
45, the risk of myocardial infarct, stroke, and all-
cause mortality was doubled in those with CKD.
Proteinuria and cardiovascular risk
In considering the value of recommending 
screening for CKD along with conventional CVD 
risk factors in selected individuals, data showing 
that the risk of CVD is better correlated with pro-
teinuria (albuminuria) than with GFR alone are 
particularly relevant, because proteinuria is virtu-
ally always a marker of kidney disease and is not 
a conventional CVD risk factor.
With regard to proteinuria as a predictor of later 
CVD, the Prevention of Renal and Vascular End-
Stage Disease (PREVEND) study showed a direct 
linear relationship between albuminuria and risk 
of CV death in the general population even at levels 
of albumin excretion generally considered within 
the normal range (15–29 mg/d) and the risk of 
CV death was increased more than sixfold when 
albumin excretion exceeded 300 mg/d.
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Recent data from the US National Health 
and Nutrition Examination Survey (NHANES) 
database as well as from Japan also document 
an independent effect of albuminuria on risk of 
both CVD and all-cause mortality at all levels of 
GFR. In patients with congestive heart failure but 
without diabetes, hypertension, or reduced GFR, 
increased urinary albumin predicts both CV and 
all-cause mortality. Similar results are obtained 
in patients with coronary disease or previous 
myocardial infarcts, in whom proteinuria con-
fers a greater risk of mortality than reduced GFR, 
although both adversely impacted outcomes.
Interestingly, not only the likelihood but also 
the time to development of a CV event is acceler-
ated significantly by the presence of proteinuria 
at all levels of GFR. Of nondiabetic subjects with 
normal serum creatinine levels undergoing per-
cutaneous coronary interventions, about 78% 
have demonstrable CKD when screened more 
stringently for renal function (estimated GFR, 
urine protein). Not only is the presence of CKD 
a likely factor in accelerating development of 
coronary disease in these patients, but it has also 
been associated with an increase in other risks, 
including hemorrhagic complications, contrast 
nephropathy, restenosis, and death. Thus multiple 
studies now confirm that proteinuria is a graded 
risk factor for CVD independent of GFR, hyper-
tension, and diabetes and that this risk extends 
down into ranges of albumin excretion generally 
considered normal. Moreover, this increased CV 
risk has been well demonstrated in several studies 
in which only dipsticks were used to screen for 
increased protein excretion.
Although there has been concern that CKD 
diagnosed by reduced GFR alone identifies pre-
dominantly older adults at increased risk because 
of age alone, the establishment of proteinuria as 
an independent risk factor for CV mortality has 
been confirmed by meta-analysis of 22 separate, 
general-population, cohort studies and in both 
older (>65) and younger people of several nation-
alities and ethnic groups.
Can treatment of chronic kidney disease reduce 
cardiovascular disease?
Finally, and most importantly from a clinical per-
spective, there are provocative data to suggest that 
renal-targeted interventions designed to reduce 
proteinuria and slow progression of CKD can 
reduce CVD risk as well. Angiotensin-converting 
enzyme inhibitors (ACEIs) and/or angiotensin 
receptor blockers are of documented benefit in 
slowing progression of established diabetic and 
nondiabetic CKD. It is interesting, with regard to 
slowing progression, that the incidence of CVD in 
CKD is significantly higher with more rapid loss 
of GFR independent of other risk factors, suggest-
ing that interventions that slow progression may 
also reduce CVD. A 44% reduction in CV mor-
tality over 4 years has been reported in patients 
screened from a general population with no risk 
factors except increased albumin in the urine and 
treated with renal-targeted ACEI therapy. This 
effect was seen primarily in people with albumin 
excretion rates higher than 50 mg/d in a pilot 
study, and the intervention was shown to be cost 
effective in that population. CV end points were 
significantly reduced in direct proportion to the 
reduction of albuminuria with ACEI therapy, and 
albuminuria proved to be the only predictor of CV 
outcome. Other studies have also demonstrated 
that changes in proteinuria (in diabetics) better 
predict outcomes than changes in blood pressure 
achieved with ACEI therapy. The potential ben-
efit of renal-targeted therapies has recently been 
highlighted by observations that higher doses 
of renin–angiotensin system blockers than are 
required for blood pressure control alone can fur-
ther reduce proteinuria indepen dently of effects 
on blood pressure or GFR, and that addition of 
salt restriction or diuretics, both very inexpensive 
interventions, can further enhance the proteinu-
ria-reducing effect of renin–angiotensin system 
blockade. Data are not yet available to establish 
that screening for CKD and subsequent interven-
tions will reduce CV mortality and be cost effec-
tive in younger people (<55). However, it is now 
known that albuminuria is a better predictor of 
renal and cardiovascular events than blood pres-
sure alone, that reducing proteinuria is more renal 
protective and cardioprotective than lowering 
blood pressure alone, and that identification of 
CKD can improve CV outcomes.
Conclusion
As celebrations of the sixth World Kidney Day on 
10 March 2011 approach, it is worth noting that 
before the past decade, kidney disease was seen 
by most government and public-health authori-
ties as being largely confined to patients with end-
stage renal disease—thankfully a rare condition, 
because the enormous cost of renal replacement 
therapy disproportionately consumes scarce 
health-care resources and is well beyond the 
means of countries inhabited by more than 80% 
of the world’s population. Much has changed. We 
now appreciate that kidney disease is not rare—
some 10% of the population has evidence of renal 
dysfunction. And we know that these individuals 
are of concern not just because a few will progress 
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to end-stage renal disease, but more because they 
carry a greatly enhanced risk of premature death 
from CVD, the single largest and most expensive 
health-care threat we confront at a global level. 
Just as progress is being made in treating most of 
the traditional CV risk factors, CKD has emerged 
as yet another one that causes substantial vas-
cular toxicity independently. Fortunately, there 
is good news as well. Biomarkers of CKD (pro-
teinuria, estimated GFR) are easy and relatively 
inexpensive to detect, and one of these, proteinu-
ria, emerges early in the evolution of generalized 
vascular disease. Thus kidney-targeted detection 
and prevention programs seem to offer a valuable 
opportunity to institute early preventive meas-
ures that go beyond traditional cardioprotective 
approaches. There is now compelling evidence 
that including selective screening for CKD in 
global health programs designed primarily 
to reduce CVD will significantly improve the 
outcomes of not only renal disease, but espe-
cially the NCDs such as diabetes and CVD that 
dominate future health-care strategies. Road 
maps for accomplishing this have already been 
presented for both developed and emerging 
countries. However, effective implementation 
of such strategies will come only when both the 
general public and the renal community work 
together to convince health authorities it is in the 
public interest to do this. It is our sincere hope 
that worldwide celebration of World Kidney Day 
2011 will provide an oppor tunity to reinforce the 
message that kidney disease is indeed common, 
harmful, and treatable and that protecting your 
kidneys is an important health strategy that may 
save your heart.
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